These results imply that PARP-1 could be used as a potential clinical tool for personalized medicine, since patients with elevated expression of PARP-1 and wild-type p53 could benefit from PARPi therapies, meanwhile it could be adverse for those carrying tumours with mutant p53 and high PARP-1 expression. This evidence concerns the gene TP53 and neoplasm.